Age at onset in genetic prion disease and the design of preventive clinical trials
Authors:
- Eric Vallabh MinikelEMEric Vallabh Minikel
- Sonia M. VallabhSVSonia M. Vallabh
- Margaret C. OrsethMOMargaret C. Orseth
- Jean-Philippe BrandelJBJean-Philippe Brandel
- Stéphane HaïkSHStéphane Haïk
- Jean-Louis LaplancheJLJean-Louis Laplanche
- Inga ZerrInga Zerr
- Piero ParchiPPPiero Parchi
- Sabina CapellariSCSabina Capellari
- Jiri SafarJSJiri Safar
- Janna KennyJKJanna Kenny
- Jamie C. FongJFJamie C. Fong
- 9 July 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 93 (2) , e125-e134
Abstract
Objective To determine whether preventive trials in genetic prion disease could be designed to follow presymptomatic mutation carriers to onset of disease. Methods We assembled age at onset or death data from 1,094 individuals with high penetrance mutations in the prion protein gene (PRNP) in order to generate survival and hazard curves and test for genetic modifiers of age at onset. We used formulae and simulations to estimate statistical power for clinical trials. Results Genetic prion disease age at onset varies over several decades for the most common mutations and neither sex, parent9s age at onset, nor PRNP codon 129 genotype provided additional explanatory power to stratify trials. Randomized preventive trials would require hundreds or thousands of at-risk individuals in order to be statistically powered for an endpoint of clinical onset, posing prohibitive cost and delay and likely exceeding the number of individuals available for such trials. Conclusion The characterization of biomarkers suitable to serve as surrogate endpoints will be essential for the prevention of genetic prion disease. Parameters such as longer trial duration, increased enrollment, and the use of historical controls in a postmarketing study could provide opportunities for subsequent determination of clinical benefit.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s diseaseActa Neuropathologica, 2013
- Sting of Alzheimer's failures offset by upcoming prevention trialsNature Reviews Drug Discovery, 2012
- Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNPHuman Molecular Genetics, 2011
- Prospective 10-year surveillance of human prion diseases in JapanBrain, 2010
- CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approachesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010
- Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international seriesBrain, 2008
- Orally Administered Amyloidophilic Compound Is Effective in Prolonging the Incubation Periods of Animals Cerebrally Infected with Prion Diseases in a Prion Strain-Dependent MannerJournal of Virology, 2007
- Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneityBrain, 2006
- Prion disease geneticsEuropean Journal of Human Genetics, 2006
- Spontaneous mutations in the prion protein gene causing transmissible spongiform encephalopathyAnnals of Neurology, 2002